Tirzepatide is a dual Glucose-dependent Insulinotropic Polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes.
A new study by Prof Stefano Del Prato, MD and team has revealed that in people with type 2 diabetes and elevated cardiovascular risk, tirzepatide, showed greater efficacy than glargine in HbA1c reduction with a lower incidence of hypoglycaemia at 52 weeks.
Further adults with type 2 diabetes with increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine in detailed results from SURPASS-4 clinical trial.
These findings are published in The Lancet journal.
For more information:
[ Ссылка ]
Get the latest medical and heath news at medicaldialogues.in
